Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Genomic instability is a hallmark of cancer related to DNA damage response (DDR)
deficiencies, offering vulnerabilities for targeted treatment. Poly (ADP-ribose) polymerase …

Context Immune therapy has emerged as a powerful treatment of metastatic urothelial
carcinoma. Over 20 ongoing studies are exploring this strategy in the neoadjuvant setting in …

Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …

DNA damage response (DDR) deficiencies result in genome instability, which is one of the
hallmarks of cancer. Poly (ADP-ribose) polymerase (PARP) enzymes take part in various …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

PURPOSE Homologous recombination repair gene mutations (HRRm) are common in
urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase …

Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in
patients with previously treated locally advanced/unresectable or metastatic urothelial …

Objective Considering the striking evidence revealed by immunotherapy in advanced or
metastatic bladder cancer, investigators have explored neoadjuvant immunotherapy and …

Simple Summary Chromosome instability (CIN) is characterized by an increased
accumulation of numerical and structural changes in chromosomes and is a common feature …